Clinical trial recruitment ads: what research sites can say and where

Many independent practices take part in clinical research, either as a site for a sponsor’s study or by running their own investigator-initiated trials. Enrollment is often the hardest part. Sites turn to flyers, social posts, search ads and their own websites to find volunteers, and those ads are held to rules that ordinary practice marketing is not.

The core idea is simple: FDA treats an ad for study volunteers as the start of informed consent, so the ad has to be reviewed like the consent document and cannot promise what the study cannot deliver. This guide covers IRB review, wording to avoid, what an ad may include, Google Ads rules, screening calls and forms, then lists recruitment ideas that work inside those rules. How a site markets itself to sponsors and CROs, rather than to patients, is in our guide to marketing a clinical research site.

Recruitment ads are part of informed consent

Under 21 CFR 50.20, an investigator must seek consent only under circumstances that give the prospective subject sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence. Under 21 CFR 56.111(a)(3), an IRB approving research must determine that selection of subjects is equitable, and be particularly aware of the special problems of research involving vulnerable populations.

FDA’s information sheet Recruiting Study Subjects connects those rules to advertising. It says FDA considers direct advertising for study subjects to be the start of the informed consent and subject selection process, and that advertisements should be reviewed and approved by the IRB as part of the package for initial review. If you decide to advertise later, the ad may be treated as an amendment to the ongoing study, and simple ads that are easily compared to the approved consent document may be reviewed by expedited means.

Direct advertising, in FDA’s words, includes newspaper, radio, TV, bulletin boards, posters and flyers intended for prospective subjects. The information sheet predates social media and search ads, but the same logic applies to any message meant to be seen by prospective volunteers, so most sites submit digital ads, landing pages and social posts to the IRB as well. Ask your IRB what it expects to see.

FDA lists what is not direct advertising: communications intended for health professionals, such as doctor-to-doctor letters, news stories, and publicity aimed at other audiences such as investors. It also says IRB review of internet trial listings is not required when the listing system limits the information to basic trial information, such as the title, purpose, protocol summary, basic eligibility criteria, site locations and how to contact the site.

Words to avoid in a study ad

FDA expects IRBs to check that an ad is not unduly coercive and does not promise a certainty of cure beyond what is outlined in the consent document and the protocol. The information sheet is specific about wording:

• No claims, express or implied, that the drug, biologic or device is safe or effective for the purposes under investigation. 21 CFR 312.7(a) bars a sponsor or investigator from representing in a promotional context that an investigational new drug is safe or effective for the purposes under investigation, and 21 CFR 812.7(d) does the same for investigational devices.
• No claims that the test article is known to be equivalent or superior to any other drug, biologic or device.
• No new treatment, new medication or new drug without explaining that the test article is investigational. FDA says a phrase such as receive new treatments leads people to believe they will get newly improved products of proven worth.
• No free medical treatment when the point is only that subjects will not be charged for taking part.
• Payment may be mentioned, but not emphasized, for example in larger or bold type.

FDA also says the IRB should review the final copy of printed ads, including the relative size of type and other visual effects, and the final recording of broadcast ads. For digital ads, that means submitting the ad as it will actually appear, including images, headline and call to action.

What a study ad may include

FDA says that, generally, an ad to recruit subjects should be limited to the information prospective subjects need to determine their eligibility and interest. When appropriately worded, the information sheet lists items that may be included, while noting that FDA does not require all of them:

1. The name and address of the clinical investigator or research facility.
2. The condition under study or the purpose of the research.
3. The eligibility criteria, in summary form.
4. A brief list of participation benefits, if any. FDA’s example is a no-cost health examination.
5. The time or other commitment required.
6. The location of the research and who to contact for more information.

A plain ad built from those items, such as a headline naming the condition and the word study, a short eligibility summary, the time commitment, the site and a contact, is usually easier for an IRB to approve than a clever one. Write it in language your volunteers understand, since 21 CFR 50.20 requires consent information to be in language understandable to the subject.

Google Ads rules for clinical trial recruitment

Google’s Clinical trial recruitment policy says Google does not allow the promotion of clinical trial recruitment in most locations. The United States is on its list of locations where it is allowed, along with countries such as Canada, the United Kingdom and Australia. Where it is allowed, three restrictions apply: prescription drugs may not be promoted, promotions may not create misleading expectations or effects of a product being tested, and promotions may not imply that the products being tested are safe.

If an ad is disapproved under this policy because you have not been approved to advertise, the policy points to Google’s application for healthcare-related advertising, with a separate application for each location or group of locations. So in practice, a study ad on Google should name the condition and the study rather than a drug, match the IRB-approved wording, and lead to a landing page that says the same thing. Our Google Ads for practices page explains how we set up healthcare campaigns, and our guide to healthcare landing pages covers the page behind the ad.

Other ad platforms have their own health and research rules. Check the current policy for each one before you launch, and keep the approved ad text, the platform version and the landing page together in your study file.

Screening calls, forms and privacy

FDA’s information sheet notes that the first contact is often with a receptionist following a script, that some scripts gather personal and sensitive information, and that the IRB should have assurance the information will be appropriately handled. It says a simple statement such as confidentiality will be maintained does not adequately inform the IRB, and lists questions an IRB may ask:

• What happens to personal information if the caller ends the interview or hangs up?
• Are the data gathered by a marketing company, and if so, are names sold to others?
• Are names of people who do not qualify kept in case they qualify for another study?
• Are paper records shredded, or put out as readable trash?

Online pre-screeners raise the same questions. A form that asks about a diagnosis, medications or symptoms collects sensitive information, so decide where the answers are stored, who sees them, how long they are kept and whether people who do not qualify are contacted again, and describe that to the IRB. Keep tracking and advertising tags away from screener pages, and do not send condition-revealing page addresses or form answers to ad platforms; see our guides to tracking pixels on practice websites and HIPAA and website contact forms.

If your practice is a HIPAA covered entity and wants to use its own patient records to find candidates, HIPAA has specific research provisions. 45 CFR 164.512(i) permits certain research uses and disclosures without authorization, for example with an IRB or privacy board waiver, or for reviews preparatory to research where the researcher represents that the review is solely to prepare a protocol or similar purposes and that no protected health information will be removed from the covered entity. Otherwise, a written authorization under 45 CFR 164.508 is generally needed. Settle the approach with your IRB, privacy officer and counsel before you contact patients, and see our guide to HIPAA marketing rules.

Use the registry listing

Many trials must be registered on ClinicalTrials.gov. Under 42 U.S.C. 282(j), registry data for applicable clinical trials includes recruitment information such as eligibility criteria, gender, age limits, whether the trial accepts healthy volunteers and overall recruitment status. Link to your study’s record from your website and ads where your IRB agrees. It gives volunteers a neutral, government-hosted description, and it keeps your own pages consistent with what the sponsor registered.

Clinical trial recruitment ideas that work inside the rules

1. A research page on your site. Which studies you run, who leads them, what taking part generally involves, how privacy is handled and how to contact the study coordinator, with each study described in IRB-approved words.
2. One landing page per study. The condition, a summary of eligibility, the time commitment, the location, payment if any stated plainly, a link to the ClinicalTrials.gov record and a contact. Submit it to the IRB with the ads that point to it.
3. Letters to referring clinicians. FDA does not treat doctor-to-doctor communication as direct advertising, but check your IRB’s and sponsor’s rules before you send them.
4. A screening script and form your IRB has seen. Short, limited to eligibility, with a clear answer on what happens to the information of people who do not qualify.
5. Fast follow-up. Volunteers who reach out often move on if nobody calls back. Staff or an AI front desk can answer logistics questions and pass study questions to the coordinator.
6. Source tracking without health data. Count which channels bring inquiries, without sending health details to ad platforms; our medical lead generation page explains how we measure that.

Sources

• FDA: Recruiting Study Subjects, Guidance for Institutional Review Boards and Clinical Investigators (information sheet, January 1998)
• 21 CFR 50.20: General requirements for informed consent
• 21 CFR 56.111: Criteria for IRB approval of research
• 21 CFR 312.7: Promotion of investigational drugs
• 21 CFR 812.7: Prohibition of promotion and other practices (investigational devices)
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 45 CFR 164.512: Uses and disclosures for which an authorization or opportunity to agree or object is not required (research, paragraph i)
• 42 U.S.C. 282: Director of National Institutes of Health (clinical trial registry, subsection j)
• Google Ads: Clinical trial recruitment policy
• Google Ads: Healthcare and medicines policy

More in Healthcare advertising guides